Dimicare Biotech is a spin-off from University Côte d'Azur (UniCA) focused on the development of a new generation of drugs against difficult-to-treat infections. Despite we are interested on different targets, our main project (DCB001) focuses on the development of a new precision treatment against MDR (multidrug-resistant) S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus).